Bradley L. Campbell serves as the President and Chief Executive Officer at Amicus Therapeutics, Inc., a position he has held since January 2009. Under his leadership, Amicus has grown from a small biotech startup into a global, commercial-stage company focused on developing and commercializing novel, high-quality medicines for rare diseases. Campbell's strategic vision has been instrumental in advancing the company's portfolio, notably with the development and approval of Galafold® (migalastat), a first-in-class oral precision medicine for Fabry disease. Before joining Amicus, Campbell amassed a wealth of experience in the biotechnology and pharmaceutical industries. He previously served as Senior Vice President of Commercial Operations at Aegerion Pharmaceuticals, where he played a key role in the global launch of Juxtapid® (lomitapide), a treatment for homozygous familial hypercholesterolemia. Earlier in his career, Campbell held various leadership positions at Pfizer, including General Manager of the Canadian business unit and Vice President of Marketing for the U.S. Primary Care business. His extensive background in both commercial and operational roles has been pivotal in driving Amicus's growth and success. As CEO of Amicus, Campbell is responsible for overseeing the company's overall strategy and operations, guiding the development of its pipeline, and ensuring the successful commercialization of its products. His leadership has been crucial in fostering a culture of innovation and patient-centricity at Amicus, as well as in building strong relationships with the global rare disease community. Under Campbell's stewardship, Amicus continues to pursue its mission of developing transformative therapies for people living with rare metabolic diseases, with a focus on expanding its reach and impact worldwide.